Effient worldwide sales slid to a tiny $3million Q4 09

Quote






Anonymous said:
I just wanted to point out that as I predicted almost a year ago- Effient is starting to really build momentum and is getting quite a bit of use nationwide. Not going to be as big as Lilly initially had hoped- but it is big enough to justify our sales force!

Cardio is the safest division in the company right now and I'm glad I made the jump over!
Click to expand...

This post-er is a stupid c*nt! There's a reason you don't make much money with Lilly, and it's because you are STUPID!!!
 






Not only have you done a horse-shit job selling effient, you've done a worse job selling insulin in the hospitals. Novo dominates you here. I propose you all loose your jobs and give the insulin back to the diabetes franchise where at least we have some hope. Give effient to the cardio group and bye bye LHG. Nobody in diabetes knows their hospital rep and when you are given a heads up that Novo is working on an exclusive in the hospital you do NOTHING!!! No accountability whatsoever! You are a pathetic sales force!!!
 






Anonymous said:
Not only have you done a horse-shit job selling effient, you've done a worse job selling insulin in the hospitals. Novo dominates you here. I propose you all loose your jobs and give the insulin back to the diabetes franchise where at least we have some hope. Give effient to the cardio group and bye bye LHG. Nobody in diabetes knows their hospital rep and when you are given a heads up that Novo is working on an exclusive in the hospital you do NOTHING!!! No accountability whatsoever! You are a pathetic sales force!!!
Click to expand...

You are complaining about one rep in your territory. Its funny at this company its "everyone else that sucks" and never them. Take responsibility for your own actions- maybe that account is small and not meaningful in the big picture. Do you know the big picture. Try seeing it from your hospital account rep's eyes. Maybe that person is a "pathetic" rep- maybe not.

And FYI Diabetes is going to be hit hard with cuts. We don't have a lot of what we consider our "top" talent in that division. Our top talent in the company jumped to cardio with Effient- and has since either left the company or is looking to go to our newer divisions like imaging. Everyone is positioning themselves- and trust me no one is going to diabetes or neuroscience- some of our weaker talents reside there.
 






Anonymous said:
Not only have you done a horse-shit job selling effient, you've done a worse job selling insulin in the hospitals. Novo dominates you here. I propose you all loose your jobs and give the insulin back to the diabetes franchise where at least we have some hope. Give effient to the cardio group and bye bye LHG. Nobody in diabetes knows their hospital rep and when you are given a heads up that Novo is working on an exclusive in the hospital you do NOTHING!!! No accountability whatsoever! You are a pathetic sales force!!!
Click to expand...

I don't know much about Effient or it's promotion. But I do know about the diabetes market. This is what I know: When I was selling for Lilly in the diabetes area, my penetration with Lilly insulins was 98%. No hospital in my assignment stocked anything other than Lilly insulin.

Because Lilly put all of it's marketing and research efforts into neuroscience due to the success of Prozac and Zyprexa, the diabetes market was ignored. Those of us sales reps at the time tried and tried to keep Lilly focused on diabetes, but we were also ingored. Lilly could have come to the market with a Lantus but didn't. Lilly could have been have been an innovator with insulins, but refused.

So now, Lilly no longer has Prozac or Zyprexa, and no longer has any clout or respect or innovation in the insulin market. It is a crying shame, and the entire blame lies with bad decisions at the top.

That's what happens when a company abandons the one that brought them to the dance.

Lilly insulin, rest in peace.
 




































Anonymous said:
So i am delusional or a liar because I my physicians have identified that the IPA on patients taking plavix, in general is not sufficient, and have a meeting 2/8 to vote on switching all patients in house that get an OAP to get effient, and have loading restricted to the cath lab, removing the risk of loading a patient that will go to cabg and does not fit our criteria.

I think if you sit back and look at the facts, and not get caught up in what Plavix reps are trying to say to distort the truth, you will see that effient is a better drug than plavix in 80% of the patients taking these drugs.

Whats funny is that many effient reps let plavix reps out detail them on their own study (timi 38). If you knew the FACTS surrounding the study, you would know that major bleeds in our group vs the plavix showed 0 statistical significance. 0! however in many areas we are allowing plavix reps to paint this picture that our bleeding is so serious. Yes in those patients that go to cabg, or in the patients older than 75, who had a previous stroke, or less tha 60 yes. The key is I negotiated with my hospitals to have it restricted to these patients to take the guess work out of this for the physicians. In the short run my manager thought i was giving away scripts, now he loves me for it.

Finally. IPA IPA IPA. You win if you repeatedly show them how weak Plavix IPA is, and compare it to Effient, then point out the recurring mi's that patients come back with. If you were a patient, would you want to be put BACK, on the same oap that you had a recurring mi on and that has shown to not be as effective as Effient, and I could be one of those non-responders that plavis reps are trying their hardest to minimize.

Effient reps, you have to stop losing your own battle. We have a superior drug, for 80% of the patients, plavix is not the issue, Time is the issue. In time we would over take plavix, but our pricing and plavix going generic is the challenge. Sooner or later almost all hosptials will start some type of ipa or genetic testing, Cardio vascular surgeons want it, ic's are starting to want it. When they do, they will realize how effient not allows loading on the table and not use as much integrellin or reopro and not as much angio max, saving them money, but also they get mich higher platlet inhibition IMMEDIATELY.

Plavix reps, great job distorting the truth nationwide. Great job getting physicians to think of the bleeding, and think this applyes to all patients. great job getting them to ignore all the recurring mi's that patients continue to have on your product, or the weak IPA. Great job getting them to ignore the repeated fda warnings, updated the heart. org's update showing the non-responders is real. Great job! However in my area it is not working.
Click to expand...

I love it, another rep trying to be a PharmD who is also an expert in statistics. I'll bet you were a communications major. Fucking idiot, you are the ones distorting the truth. 100+ million patients treated with Plavix in the real world, no issues anywhere near your "data". Clopidogrel at 4 cents a tablet will be your problem.
 






Anonymous said:
I love it, another rep trying to be a PharmD who is also an expert in statistics. I'll bet you were a communications major. Fucking idiot, you are the ones distorting the truth. 100+ million patients treated with Plavix in the real world, no issues anywhere near your "data". Clopidogrel at 4 cents a tablet will be your problem.
Click to expand...
Brilinta rep here.... I love this thread. Ironically, you are the only sales force that understands the torture that AZ management has put us reps through.
 






Anonymous said:
I love it, another rep trying to be a PharmD who is also an expert in statistics. I'll bet you were a communications major. Fucking idiot, you are the ones distorting the truth. 100+ million patients treated with Plavix in the real world, no issues anywhere near your "data". Clopidogrel at 4 cents a tablet will be your problem.
Click to expand...

FACT 10 cent pills are the reality. And the future. Deal with it. Invent something better.
 


















Anonymous said:
I used to be at Daiichi Sankyo (glad to be gone) and remember being told Effient would be a $5 Billion drug. It looks like they were wrong.
Click to expand...

It is a $5 billion drug. Lilly has invested at least that much in it. It's as much a success as the purchase of IMCLONE. Lilly leadership really knows what they are doing. Look at their track record. Follow them if you really want to make something of yourself. They is got PhD's.
 
























Anonymous said:
Total dud? Effient has saved countless lives and is arguably one of the biggest advancements in cardiology in the last 10 years. For the right patient Effient is THE drug.
Click to expand...

That's maybe a bit of hyperbole, but it is a nice product that is now doing well for its limited indications and late entrance into the market. Its certainly helped a lot of patients. $100MM / quarter in sales is nothing to sneeze at among drugs launched in the last 5 years.
 






Top Bottom
Back
Quote